Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers
The global prevalence of dementia is as high as 24 million, and has been predicted to
quadruple by the year 2050. In the US alone, Alzheimer disease (AD)–the most frequent …
quadruple by the year 2050. In the US alone, Alzheimer disease (AD)–the most frequent …
Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia
The apolipoprotein E (APOE) gene is the strongest genetic risk factor for Alzheimer's
disease and directly influences tauopathy and tau-mediated neurodegeneration. ApoE4 has …
disease and directly influences tauopathy and tau-mediated neurodegeneration. ApoE4 has …
Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases
Apolipoprotein (apo) E is a multifunctional protein with central roles in lipid metabolism,
neurobiology, and neurodegenerative diseases. It has three major isoforms (apoE2, apoE3 …
neurobiology, and neurodegenerative diseases. It has three major isoforms (apoE2, apoE3 …
Apolipoprotein E in Alzheimer's disease and other neurological disorders
Apolipoprotein E (APOE) is a 299-aminoacid protein encoded by the APOE gene. Three
common polymorphisms in the APOE gene, ɛ2, ɛ3, and ɛ4, result in a single aminoacid …
common polymorphisms in the APOE gene, ɛ2, ɛ3, and ɛ4, result in a single aminoacid …
Mild Cognitive Impairment and Alzheimer Disease: Patterns of Altered Cerebral Blood Flow at MR Imaging1
Purpose: To examine regional cerebral blood flow (rCBF) in incident mild cognitive
impairment (MCI) and Alzheimer disease (AD) by using continuous arterial spin-labeling …
impairment (MCI) and Alzheimer disease (AD) by using continuous arterial spin-labeling …
Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele
WM van der Flier, YAL Pijnenburg, NC Fox… - The Lancet …, 2011 - thelancet.com
Some patients with early-onset Alzheimer's disease (AD) present with a distinct phenotype.
Typically, the first and most salient characteristic of AD is episodic memory impairment. A …
Typically, the first and most salient characteristic of AD is episodic memory impairment. A …
Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease
Posterior cortical hypometabolism measured with 18F-fluorodeoxyglucose (FDG)-PET is a
well-known marker of Alzheimer's disease-related neurodegeneration, but its associations …
well-known marker of Alzheimer's disease-related neurodegeneration, but its associations …
Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden
GD Rabinovici, AJ Furst, A Alkalay, CA Racine… - Brain, 2010 - academic.oup.com
Patients with early age-of-onset Alzheimer's disease show more rapid progression, more
generalized cognitive deficits and greater cortical atrophy and hypometabolism compared to …
generalized cognitive deficits and greater cortical atrophy and hypometabolism compared to …
Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET
A Drzezga, T Grimmer… - Journal of Nuclear …, 2005 - Soc Nuclear Med
Patients with mild cognitive impairment (MCI) represent a risk population for progressing to
dementia of the Alzheimer type (DAT). However, clinical criteria do not ensure reliable …
dementia of the Alzheimer type (DAT). However, clinical criteria do not ensure reliable …